PHARMACEUTICALS
Untitled Page
Peregrine, continued ...
In these studies, researchers confirmed broad-spectrum PS-targeting
antibody binding to VHF viral particles and also demonstrated that
Peregrine’s PS-targeting antibodies bind to mammalian cells infected
with hemorrhagic fever viruses. Initial dosing studies showed that
PS-targeting antibodies are sustainable in the blood at therapeutically
relevant concentrations.
Additional studies presented also
showed that a single dose of a PS-targeting antibody increased the
survival of hamsters infected with lethal doses of viruses from two
different VHF virus families. Based on these findings, additional
efficacy studies, including repeat dose and combination therapy
studies, are now underway.
“The early data from our antiviral
program designed to test the potential of our PS-targeting antibodies
to prevent and treat viral hemorrhagic fevers is very encouraging, and
we are pleased to have the opportunity to present our findings at this
major meeting of our biodefense peers,” says Dr. Amy Brideau-Andersen,
head of Peregrine’s preclinical antiviral program, “Results to date are
confirming that our PS-targeting antibodies may have broad spectrum
potential against multiple viruses, which could make them valuable
against both hemorrhagic fever viruses and other biodefense
threats. Further efficacy studies are already underway and we look
forward to reporting on our progress as we continue to advance this
important program.”
<< PREVIOUS PAGE
Related headlines
Orange County Superior Court certifies Abbott suit
Orange Coast Memorial opens CyberKnife, Radiation Oncology Center
Spectrum Pharmaceuticals moves forward with bladder cancer drug
UC Irvine sees success with embryonic stem cell therapy
'OC METRO Minute,' Nov. 10: CHOC Children's plans to lay off 42
Peregrine, continued ...
In these studies, researchers confirmed broad-spectrum PS-targeting
antibody binding to VHF viral particles and also demonstrated that
Peregrine’s PS-targeting antibodies bind to mammalian cells infected
with hemorrhagic fever viruses. Initial dosing studies showed that
PS-targeting antibodies are sustainable in the blood at therapeutically
relevant concentrations. Additional studies presented also showed that a single dose of a PS-targeting antibody increased the survival of hamsters infected with lethal doses of viruses from two different VHF virus families. Based on these findings, additional efficacy studies, including repeat dose and combination therapy studies, are now underway.
“The early data from our antiviral program designed to test the potential of our PS-targeting antibodies to prevent and treat viral hemorrhagic fevers is very encouraging, and we are pleased to have the opportunity to present our findings at this major meeting of our biodefense peers,” says Dr. Amy Brideau-Andersen, head of Peregrine’s preclinical antiviral program, “Results to date are confirming that our PS-targeting antibodies may have broad spectrum potential against multiple viruses, which could make them valuable against both hemorrhagic fever viruses and other biodefense threats. Further efficacy studies are already underway and we look forward to reporting on our progress as we continue to advance this important program.”
<< PREVIOUS PAGE
Related headlines
Orange County Superior Court certifies Abbott suit
Orange Coast Memorial opens CyberKnife, Radiation Oncology Center
Spectrum Pharmaceuticals moves forward with bladder cancer drug
UC Irvine sees success with embryonic stem cell therapy
'OC METRO Minute,' Nov. 10: CHOC Children's plans to lay off 42
